News & Updates
Filter by Specialty:
Early 3-day remdesivir course may prevent COVID-19 hospitalization, death
An early, 3-day regimen of remdesivir may prevent hospitalization and death in patients with COVID-19 who are at risk for disease progression, according to results of the PINETREE study.
Early 3-day remdesivir course may prevent COVID-19 hospitalization, death
26 Jan 2022
COVID-19 unlikely to be transmitted via breastfeeding, says small study
SARS-CoV-2 RNA is infrequently detected in the breastmilk of mothers with proven or suspected COVID-19, but just the same, breastfeeding does not represent a risk factor for vertical transmission of the infection, according to data from a small study.
COVID-19 unlikely to be transmitted via breastfeeding, says small study
26 Jan 2022
Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma
The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.